Observational study of health utilities in adult primary ciliary dyskinesia patients: preliminary data on associations with molecular diagnosis, clinical phenotype and HRQOL measures

Background Primary ciliary dyskinesia (PCD) is a congenital disorder characterized by chronic respiratory morbidity. To date, there is no information on PCD-specific preference-based quality of life measures such as health utilities (HU). We cross-sectionally assessed HU in adult PCD patients and explored relationships with genotype, phenotype and quality of life (QOL)-PCD scales. Methods Diagnostic testing was performed according to international guidelines, while participants completed the visual analog scale (VAS), time trade off (TTO), standard gamble (SG), and EuroQol 5 dimensions (EQ5D) HU instruments, as well as the QOL-PCD questionnaire. Hierarchical regression was used to identify the QOL-PCD scales that are most predictive of HU. Results Among 31 patients, median HU are 0.75 (VAS), 0.86 (EQ5D), 0.91 (TTO) and 0.99 (SG). The underlying genotype is not associated with HU measures. VAS and EQ5D are associated with lung function, while TTO and SG values are not sensitive to any of the examined factors. Among the QOL-PCD scales, physical functioning and lower respiratory symptoms explained much of VAS (R2= 0.419) and EQ5D (R2= 0.538) variability. Conclusions Our study demonstrates that HU elicitation in PCD is feasible using both direct and indirect methods. Overall, HU scores are relatively high among adult patients, with higher scores observed in SG and TTO, followed by EQ5D and VAS. VAS and EQ5D HU values are sensitive to lung function as well as to QOL-PCD physical functioning and lower respiratory symptom scores.

[1]  A. Boner,et al.  Longitudinal Lung Volume Changes by Ultrastructure and Genotype in Primary Ciliary Dyskinesia. , 2021, Annals of the American Thoracic Society.

[2]  K. Kyriacou,et al.  Implementation of multigene panel NGS diagnosis in the national primary ciliary dyskinesia cohort of Cyprus: An island with a high disease prevalence , 2021, Human mutation.

[3]  Wanqing Chen,et al.  Comparing EQ-5D-3L and EQ-5D-5L performance in common cancers: suggestions for instrument choosing , 2020, Quality of Life Research.

[4]  P. Yiallouros,et al.  Health related quality of life in adult primary Ciliary dyskinesia patients in Cyprus: development and validation of the Greek version of the QOL-PCD questionnaire , 2020, Health and Quality of Life Outcomes.

[5]  N. Kiper,et al.  Genotype and phenotype evaluation of patients with primary ciliary dyskinesia: First results from Turkey , 2019, Pediatric pulmonology.

[6]  A. Quittner,et al.  Validation of pediatric health‐related quality of life instruments for primary ciliary dyskinesia (QOL‐PCD) , 2019, Pediatric pulmonology.

[7]  K. Kyriacou,et al.  Wide phenotypic variability in RSPH9-associated primary ciliary dyskinesia: review of a case-series from Cyprus. , 2019, Journal of thoracic disease.

[8]  L. Behan,et al.  Translation of the quality-of-life measure for adults with primary ciliary dyskinesia and its application in patients in Brazil , 2019, Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia.

[9]  T. Ferkol,et al.  Advances in the Genetics of Primary Ciliary Dyskinesia: Clinical Implications , 2018, Chest.

[10]  Liu Liu,et al.  Health state utilities and subjective well-being among psoriasis vulgaris patients in mainland China , 2018, Quality of Life Research.

[11]  Tobias Welte,et al.  Computed tomography in adult patients with primary ciliary dyskinesia: Typical imaging findings , 2018, PloS one.

[12]  K. Kyriacou,et al.  The effect of l-Arginine on Ciliary Beat Frequency in PCD patients, non-PCD respiratory patients and healthy controls. , 2018, Pulmonary pharmacology & therapeutics.

[13]  E. Picard,et al.  Clinical impact of Pseudomonas aeruginosa colonization in patients with Primary Ciliary Dyskinesia. , 2017, Respiratory medicine.

[14]  J. Yfantopoulos,et al.  Validation and comparison of the psychometric properties of the EQ-5D-3L and EQ-5D-5L instruments in Greece , 2017, The European Journal of Health Economics.

[15]  B. Karadag,et al.  Quality of Life Questionnaire for Turkish Patients with Primary Ciliary Dyskinesia. , 2017, Turkish thoracic journal.

[16]  A. Quittner,et al.  Validation of a health-related quality of life instrument for primary ciliary dyskinesia (QOL-PCD) , 2017, Thorax.

[17]  H. Omran,et al.  European Respiratory Society guidelines for the diagnosis of primary ciliary dyskinesia , 2017, European Respiratory Journal.

[18]  B. Housset,et al.  Clinical characteristics, functional respiratory decline and follow-up in adult patients with primary ciliary dyskinesia , 2016, Thorax.

[19]  D. Hansell,et al.  A longitudinal study characterising a large adult primary ciliary dyskinesia population , 2016, European Respiratory Journal.

[20]  G. Iskrov,et al.  Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe , 2016, The European Journal of Health Economics.

[21]  A. Quittner,et al.  A quality-of-life measure for adults with primary ciliary dyskinesia: QOL–PCD , 2015, European Respiratory Journal.

[22]  Joshua T. Cohen,et al.  The changing face of the cost-utility literature, 1990-2012. , 2015, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[23]  M. Rosenfeld,et al.  Clinical features of childhood primary ciliary dyskinesia by genotype and ultrastructural phenotype. , 2015, American journal of respiratory and critical care medicine.

[24]  Marc Carrier,et al.  Validity of standard gamble estimated quality of life in acute venous thrombosis. , 2014, Thrombosis research.

[25]  E. Kerem,et al.  Differences in disease expression between primary ciliary dyskinesia and cystic fibrosis with and without pancreatic insufficiency. , 2014, Chest.

[26]  J. Shendure,et al.  Mutations in RSPH1 cause primary ciliary dyskinesia with a unique clinical and ciliary phenotype. , 2014, American journal of respiratory and critical care medicine.

[27]  M. Versteegh,et al.  Time trade-off: one methodology, different methods , 2013, The European Journal of Health Economics.

[28]  M. Boon,et al.  Primary ciliary dyskinesia, an orphan disease , 2013, European Journal of Pediatrics.

[29]  A. Clément,et al.  Longitudinal lung function and structural changes in children with primary ciliary dyskinesia , 2012, Cilia.

[30]  J. Bradley,et al.  Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study , 2012, European Respiratory Journal.

[31]  S. Stanojevic,et al.  Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations , 2012, European Respiratory Journal.

[32]  A. Bezjak,et al.  Patterns of reporting health-related quality of life outcomes in randomized clinical trials: implications for clinicians and quality of life researchers , 2011, Quality of Life Research.

[33]  G. Bonsel,et al.  Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L) , 2011, Quality of Life Research.

[34]  L. Skovgaard,et al.  Lung function in patients with primary ciliary dyskinesia: a cross-sectional and 3-decade longitudinal study. , 2010, American journal of respiratory and critical care medicine.

[35]  R. Goeree,et al.  A review of health utilities across conditions common in paediatric and adult populations , 2010, Health and quality of life outcomes.

[36]  A. Boner,et al.  Health-related quality of life and unmet needs in patients with primary ciliary dyskinesia , 2009, European Respiratory Journal.

[37]  David T Arnold,et al.  Comparison of direct and indirect methods of estimating health state utilities for resource allocation: review and empirical analysis , 2009, BMJ : British Medical Journal.

[38]  W. Dreschler,et al.  Choosing between measures: comparison of EQ-5D, HUI2 and HUI3 in persons with hearing complaints , 2007, Quality of Life Research.

[39]  Murtuza Bharmal,et al.  Comparing the EQ-5D and the SF-6D descriptive systems to assess their ceiling effects in the US general population. , 2006, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  I. Mcmanus,et al.  Stigmatization, Physical Illness and Mental Health in Primary Ciliary Dyskinesia , 2006, Journal of health psychology.

[41]  D. Niakas,et al.  Overcoming inherent problems of preference-based techniques for measuring health benefits: An empirical study in the context of kidney transplantation , 2006, BMC Health Services Research.

[42]  I. Mcmanus,et al.  Primary ciliary dyskinesia (Siewert's / Kartagener's Syndrome): Respiratory symptoms and psycho-social impact , 2003, BMC pulmonary medicine.

[43]  F. Salaffi,et al.  Responsiveness of Health Status Measures and Utility-based Methods in Patients with Rheumatoid Arthritis , 2002, Clinical Rheumatology.

[44]  J. Tsevat Response to Lenert and Kaplan: What Do Utilities Measure? , 2000 .

[45]  J Tsevat,et al.  What do utilities measure? , 2000, Medical care.

[46]  A Gafni,et al.  The standard gamble method: what is being measured and how it is interpreted. , 1994, Health services research.

[47]  E. Nord,et al.  The validity of a visual analogue scale in determining social utility weights for health states. , 1991, The International journal of health planning and management.

[48]  S. Paisley,et al.  How do individuals value health states? A qualitative investigation. , 2017, Social science & medicine.

[49]  S. Parlee,et al.  This Work Is Licensed under a Creative Commons Attribution-noncommercial 4.0 International License , 2022 .